tiprankstipranks
Advertisement
Advertisement

CRBP Stock Latest News

Corbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
The FlyCorbus Pharmaceuticals price target lowered to $52 from $54 at Oppenheimer
4d ago
CRBP
Corbus Pharmaceuticals management to meet with Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals management to meet with Oppenheimer
11d ago
CRBP
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
PremiumThe Fly
Corbus Pharmaceuticals price target lowered to $30 from $38 at Wedbush
25d ago
CRBP
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
PremiumRatings
Buy Rating Reaffirmed on CRB-701’s Emerging Efficacy and Undervalued Potential; $38 Price Target Maintained
26d ago
CRBP
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
PremiumThe Fly
Corbus Pharmaceuticals share selloff overdone, says Guggenheim
26d ago
CRBP
Buy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
PremiumRatingsBuy Rating Reiterated on CRB-701’s Best-in-Class Potential and De-Risked Path to Registrational Trial; $40 Price Target Maintained
26d ago
CRBP
Corbus Highlights Promising CRB-701 Data in HPV Cancers
Premium
Company Announcements
Corbus Highlights Promising CRB-701 Data in HPV Cancers
26d ago
8K
CRBP
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
Premium
The Fly
Corbus Pharmaceuticals reports updated CRB-701 Phase 1/2 data
26d ago
CRBP
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
PremiumThe Fly
Corbus Pharmaceuticals price target raised to $44 from $40 at Mizuho
1M ago
CRBP
Corbus Pharmaceuticals Appoints First Chief Business Officer
PremiumCompany Announcements
Corbus Pharmaceuticals Appoints First Chief Business Officer
1M ago
8K
CRBP
Corbus Pharmaceuticals names Nishant Saxena as chief business officer
PremiumThe Fly
Corbus Pharmaceuticals names Nishant Saxena as chief business officer
1M ago
CRBP
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
PremiumCompany Announcements
Corbus Pharmaceuticals Adds Independent Director Amid Governance Updates
1M ago
8K
CRBP
Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential
PremiumRatingsAnalyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential
1M ago
CRBP
Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer
Premium
The Fly
Corbus Pharmaceuticals price target lowered to $54 from $57 at Oppenheimer
1M ago
CRBP
Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
Premium
The Fly
Corbus Pharmaceuticals price target lowered to $33 from $36 at Jefferies
1M ago
CRBP
Corbus Pharmaceuticals reports Q1 EPS ($1.23), consensus ($1.22)
PremiumThe Fly
Corbus Pharmaceuticals reports Q1 EPS ($1.23), consensus ($1.22)
1M ago
CRBP
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook
PremiumCompany Announcements
Corbus Highlights Oncology, Obesity Pipeline Progress and Outlook
1M ago
8K
CRBP
MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts
PremiumWeekend Updates
MercadoLibre, T-Mobile, Corbus, Celestica, Elevance Trending With Analysts
2M ago
CLS
ELV
Spotify upgraded, Alibaba initiated: Wall Street’s top analyst calls
PremiumThe Fly
Spotify upgraded, Alibaba initiated: Wall Street’s top analyst calls
2M ago
CLS
CNC
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
PremiumThe FlyCorbus Pharmaceuticals initiated with a Buy at Guggenheim
2M ago
CRBP
Corbus Pharmaceuticals Initiated at Buy on CRB-701 Head and Neck Cancer Opportunity, Undervalued Pipeline, and $45 Price Target
Premium
Ratings
Corbus Pharmaceuticals Initiated at Buy on CRB-701 Head and Neck Cancer Opportunity, Undervalued Pipeline, and $45 Price Target
2M ago
CRBP
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
Premium
The Fly
Corbus Pharmaceuticals initiated with a Buy at Guggenheim
2M ago
CRBP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >